Protalix BioTherapeutics

Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024

Retrieved on:

星期五, 五月 3, 2024

Protalix BioTherapeutics, Calendar, EDT, Webcast

CARMIEL, Israel, May 3, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended March 31, 2024 and provide a business and clinical update on May 10, 2024.

Key Points:

Management will host a conference call with investors to discuss the financial results and provide an update on recent corporate and regulatory developments.
The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.
Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software.
A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.

Zacks Launched the Israel 150 Platform

Retrieved on:

星期二, 三月 12, 2024

Research, Protalix BioTherapeutics, Tower Semiconductor, Zacks, Enlight Renewable Energy, Geography, Eltek, Cryptocurrency

CHICAGO, March 12, 2024 /PRNewswire/ -- Zacks Investment Research, a leading provider of investment-related data, research, and commentary, proudly announces the launch of Zacks Israel 150 - https://israel150.zacks.com. This new platform focuses on Israeli companies listed on US exchanges, providing global investors with easy access to valuable information.

Key Points:

CHICAGO, March 12, 2024 /PRNewswire/ -- Zacks Investment Research, a leading provider of investment-related data, research, and commentary, proudly announces the launch of Zacks Israel 150 - https://israel150.zacks.com .
Zacks Israel 150 allows investors to rank Israeli equities based on criteria such as annual sales, market cap, assets, exchange, industry, and sectors.
Companies listed on Zacks Israel 150 gain extensive visibility in the US investment community through Zacks' renowned distribution platform.
At Zacks Investment Research, the Israel 150 platform represents the initial step in leveraging the advanced distribution platform to offer investors convenient access to investment opportunities categorized by geography, sectors, and other criteria.

Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024

Retrieved on:

星期四, 三月 7, 2024

EDT, Protalix BioTherapeutics, Webcast

CARMIEL, Israel, March 7, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the fiscal year ended December 31, 2023 and provide a business update on Thursday, March 14, 2024.

Key Points:

Company to host conference call and webcast at 8:30 a.m. EDT
CARMIEL, Israel, March 7, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the fiscal year ended December 31, 2023 and provide a business update on Thursday, March 14, 2024.
Management will host a conference call with investors to discuss the financial results and provide a business update.

Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference

Retrieved on:

星期五, 二月 23, 2024

BIO, Conference, Protalix BioTherapeutics

CARMIEL, Israel, Feb. 23, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced that it will attend and present at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 at the New York Marriott Marquis in New York City.

Key Points:

Corporate presentation scheduled for Monday, February 26, 2024 at 1:00 PM ET
CARMIEL, Israel, Feb. 23, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced that it will attend and present at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 at the New York Marriott Marquis in New York City.
Management is scheduled to give a corporate overview at the BIO CEO & Investor Conference on Monday, February 26, 2024 at 1:00 PM ET at the Plymouth Room and will be available to participate in one-on-one partnering meetings with registered investors and other conference attendees.
Following the presentation, a copy will be available under the Event Calendar tab in the Investors section of the Company's website.
Conference attendees that would like to schedule a meeting with the Company's management are encouraged to register through the BIO CEO attendee portal.

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

星期五, 十二月 1, 2023

Biotechnology, Health, Genetics, Pharmaceutical, Oncology, ATRA, Epstein–Barr virus, Protalix BioTherapeutics, EBV, Patient, Employment, Compensated emancipation, Cancer, Pharmaceutical industry, Thermoplastic

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 27,000 restricted stock units of Atara’s common stock to three newly hired employees.

Key Points:

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 27,000 restricted stock units of Atara’s common stock to three newly hired employees.
These awards were approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of December 1, 2023, as an inducement material to the new employees entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date and the remainder vesting in 12 approximately equal quarterly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates.

Aro Biotherapeutics Secures $41.5M Series B Financing

Retrieved on:

星期二, 十一月 28, 2023

FDA, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Protalix BioTherapeutics, Series, Patient, Small RNA, Pharmaceutical industry

Aro Biotherapeutics, a clinical stage biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced it has secured $41.5M in a Series B funding round.

Key Points:

Aro Biotherapeutics, a clinical stage biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced it has secured $41.5M in a Series B funding round.
The round was led by Cowen Healthcare Investments, with participation from existing investors from Aro’s Series A financing round in 2020, including Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Northpond Ventures, Healthcap and BVF Partners, L.P.
In conjunction with the financing, Christopher Picariello, President, JJDC, has joined Aro’s Board of Directors.
In addition, the Series B funding will support new Centyrin-siRNA conjugate programs focused on the discovery of new therapies for autoimmune disorders.

Codexis Reports Third Quarter 2023 Financial Results

Retrieved on:

星期四, 十一月 2, 2023

REDWOOD CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the third quarter ended September 30, 2023, and provided a business update.

Key Points:

Company to Host Virtual ECO Synthesis™ Platform-Focused KOL Event on December 8, 2023, featuring John Maraganore
REDWOOD CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the third quarter ended September 30, 2023, and provided a business update.
Including enzyme sales related to PAXLOVID™, total revenues were $9.3 million in third quarter 2023 compared to $34.5 million in third quarter 2022.
Including enzyme sales related to PAXLOVID™, product revenues were $5.4 million in third quarter 2023 compared to $28.0 million in third quarter 2022.
Product gross margin, excluding enzyme sales related to PAXLOVID™, was 58% for third quarter 2023 compared to 55% in third quarter 2022.

Calidi Biotherapeutics Announces Appointment of Andrew Jackson as Chief Financial Officer

Retrieved on:

星期一, 十月 30, 2023

Calidi Biotherapeutics, Inc. (NYSEAM: CLDI) (or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the appointment of Andrew Jackson as Chief Financial Officer.

Key Points:

Calidi Biotherapeutics, Inc. (NYSEAM: CLDI) (or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the appointment of Andrew Jackson as Chief Financial Officer.
Mr. Jackson most recently served as Chief Financial Officer of Eterna Therapeutics Inc. from May 2022 to May 2023.
He also served as Chief Financial Officer at AltheaDx, Inc., a commercial stage molecular diagnostics company specializing in precision medicine.
“I am excited to join Calidi at such a pivotal time for the company and proud to join their mission to develop novel immunotherapies that have the potential to transform the way we treat cancer,” said Andrew Jackson, Chief Financial Officer of Calidi Biotherapeutics.

Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023

Retrieved on:

星期一, 十月 30, 2023

EST, Protalix BioTherapeutics, Calendar, Webcast, Broadcasting

CARMIEL, Israel, Oct. 30, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will release its financial results for the third quarter ended September 30, 2023 and provide a business update on Monday, November 6, 2023.

Key Points:

Company to host conference call and webcast at 8:30 a.m. EST
CARMIEL, Israel, Oct. 30, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will release its financial results for the third quarter ended September 30, 2023 and provide a business update on Monday, November 6, 2023.
Management will host a conference call with investors to discuss the financial results and provide an update on recent corporate and regulatory developments.
The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.
A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.

Excision BioTherapeutics Announces Presentation of Interim Clinical Data for EBT-101 in Latent HIV at Upcoming European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress

Retrieved on:

星期四, 十月 19, 2023

CRISPR, George Washington University School of Medicine & Health Sciences, Safety, Trial of the century, HIV, Washington University School of Medicine, Cell, European Society of Gene and Cell Therapy, Protalix BioTherapeutics, SAN, ESGCT, Pharmaceutical industry

SAN FRANCISCO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies to cure viral infectious diseases, today announced that interim clinical safety and biodistribution data will be presented at the 30th European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress, which will be held from October 24-27, 2023, in Brussels, Belgium.

Key Points:

SAN FRANCISCO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies to cure viral infectious diseases, today announced that interim clinical safety and biodistribution data will be presented at the 30th European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress, which will be held from October 24-27, 2023, in Brussels, Belgium.
Dr. Rachel Presti of Washington University School of Medicine, a principal investigator for the clinical evaluation of EBT-101, will offer the first look at interim safety and biodistribution data from the EBT-101-001 Phase 1/2 clinical trial.
EBT-101 is being evaluated in a first-in-human clinical study to assess its safety and efficacy in people with HIV on antiretroviral therapy.
The presentation details are listed below, and the full program is available on the ESGCT website .